<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03552445</url>
  </required_header>
  <id_info>
    <org_study_id>2013GR0005</org_study_id>
    <nct_id>NCT03552445</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of a Tetanus-diphtheria Vaccine and a 13-valent Pneumococcal Conjugate Vaccine</brief_title>
  <official_title>Immunogenicity and Safety of a Tetanus-diphtheria Vaccine and a 13-valent Pneumococcal Conjugate Vaccine After Concomitant Vaccination in ≥50-year-old Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea University Guro Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea University Guro Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      When two or more vaccines are administered concurrently, there is a concern on vaccine
      interaction, which can either enhance or suppress immune response to vaccine antigens. This
      study is designed to evaluate the immunogenicity and safety of tetanus-diphtheria (Td) and
      pneumococcal vaccines after concomitant administration in adults aged 50 years and older.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vaccination would be the most effective strategy to prevent diverse infectious diseases.
      Actually, The World Health Organization (WHO) estimate that vaccination averts 2-3 million
      deaths per year. In adults, several vaccines are recommended based on age and medical
      conditions if they have not receive vaccination before, and lack evidence of past infection:
      influenza, measles-mumps-rubella (MMR), varicella, human papilloma virus (HPV),
      tetanus-diphtheria (Td), pneumococcl vaccines and etc. In particular, when the patient visits
      a vaccination clinic, Td and the pneumococcal vaccines are commonly administered at the same
      time. In this study, we aimed to evaluate the immunogenicity and safety of Td vaccine and
      PCV13 after concomitant administration in adults aged 50 years. This single-center, open
      label randomized trial was conducted (Clinical Trial Number - NCT02215863) at Korea
      University Guro Hospital from November 2013 to April 2016. Adults ≥50 years of age were
      randomized in a 1:1:1 ratio to receive Td + PCV13 (Group 1), PCV13 alone (Group 2) or Td
      alone (Group 3).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2013</start_date>
  <completion_date type="Actual">February 28, 2018</completion_date>
  <primary_completion_date type="Actual">April 30, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tetanus antibody titers at day 28 post-vaccination</measure>
    <time_frame>4 weeks after vaccination</time_frame>
    <description>IgG antibody titers by enzyme linked immunosorbent assay (ELISA) Seroprotection rate: percentage of subjects with a post-vaccination antibody levels ≥0.1 IU/mL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diphtheria antibody titers at day 28 post-vaccination</measure>
    <time_frame>4 weeks after vaccination</time_frame>
    <description>IgG antibody titers by enzyme linked immunosorbent assay (ELISA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tetanus seroprotection rate at day 28 post-vaccination</measure>
    <time_frame>4 weeks after vaccination</time_frame>
    <description>Proportion of IgG antibody titers ≥0.1 IU/mL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diphtheria seroprotection rate at day 28 post-vaccination</measure>
    <time_frame>4 weeks after vaccination</time_frame>
    <description>Proportion of IgG antibody titers ≥0.1 IU/mL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Opsonophagocytic assay (OPA) titers for PCV13</measure>
    <time_frame>4 weeks after vaccination</time_frame>
    <description>Four capsule serotypes: 1, 5, 18C and 19A</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Frequency and duration of local and systemic adverse events</measure>
    <time_frame>During 4 weeks after vaccination</time_frame>
    <description>The safety profiles of co-administration of Td and PCV13 will be compared to those of single vaccination.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">462</enrollment>
  <condition>Tetanus</condition>
  <condition>Diphtheria</condition>
  <condition>Pneumococcal Infections</condition>
  <arm_group>
    <arm_group_label>Tetanus-diphtheria (Td) and PCV13</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PCV13 alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Td alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tetanus-diphtheria (Td) and PCV13</intervention_name>
    <description>154 concomitant Td-PCV13 recipients: one dose of each vaccine administered on Day 0</description>
    <arm_group_label>Tetanus-diphtheria (Td) and PCV13</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PCV13 alone</intervention_name>
    <description>154 PCV13 recipients: one vaccine injection administered on Day 0</description>
    <arm_group_label>PCV13 alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Td alone</intervention_name>
    <description>437 Td recipients: one vaccine injection administered on Day 0</description>
    <arm_group_label>Td alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults aged ≥50 years who signed the informed consent

        Exclusion Criteria:

          -  history of S. pneumoniae infection within the previous 5 years

          -  previous pneumococcal vaccination

          -  previous tetanus-diphtheria (Td) vaccination within the last 10 years

          -  known immunodeficiency or immunosuppressant use or coagulation disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>May 17, 2018</study_first_submitted>
  <study_first_submitted_qc>May 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2018</study_first_posted>
  <last_update_submitted>May 29, 2018</last_update_submitted>
  <last_update_submitted_qc>May 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Korea University Guro Hospital</investigator_affiliation>
    <investigator_full_name>Joon Young Song</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tetanus</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
    <mesh_term>Pneumococcal Infections</mesh_term>
    <mesh_term>Tetany</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

